BR112014013041A2 - uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco - Google Patents

uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco

Info

Publication number
BR112014013041A2
BR112014013041A2 BR112014013041A BR112014013041A BR112014013041A2 BR 112014013041 A2 BR112014013041 A2 BR 112014013041A2 BR 112014013041 A BR112014013041 A BR 112014013041A BR 112014013041 A BR112014013041 A BR 112014013041A BR 112014013041 A2 BR112014013041 A2 BR 112014013041A2
Authority
BR
Brazil
Prior art keywords
treatment
dry eye
eye syndrome
signal transduction
cell permeation
Prior art date
Application number
BR112014013041A
Other languages
English (en)
Inventor
Deloche Catherine
Combette Jean-Marc
Original Assignee
Xigen Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Inflammation Ltd filed Critical Xigen Inflammation Ltd
Publication of BR112014013041A2 publication Critical patent/BR112014013041A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

resumo patente de invenção: "uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco". a presente invenção refere-se ao uso de inibidores de proteína quinase e mais especificamente ao uso de inibidores da proteína quinase de quinase c-jun amino-terminal, (poli-)peptídeos inibidores de jnk, peptídeos quiméricos, ou de ácidos nucleicos codificando os mesmos bem como composições farmacêuticas contendo os mesmos, para o tratamento de síndrome do olho seco.
BR112014013041A 2011-11-30 2012-11-30 uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco BR112014013041A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011006003 2011-11-30
PCT/EP2012/004952 WO2013079213A1 (en) 2011-11-30 2012-11-30 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome

Publications (1)

Publication Number Publication Date
BR112014013041A2 true BR112014013041A2 (pt) 2019-09-24

Family

ID=47324033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013041A BR112014013041A2 (pt) 2011-11-30 2012-11-30 uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco

Country Status (12)

Country Link
US (1) US20140309400A1 (pt)
JP (1) JP2015500213A (pt)
KR (1) KR20140099526A (pt)
CN (1) CN104023736A (pt)
AU (1) AU2012344299A1 (pt)
BR (1) BR112014013041A2 (pt)
CA (1) CA2855223A1 (pt)
EA (1) EA201491062A1 (pt)
IL (1) IL232699A0 (pt)
MX (1) MX2014006399A (pt)
SG (1) SG11201402347YA (pt)
WO (1) WO2013079213A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CN107428805B (zh) * 2015-02-25 2021-01-08 台湾基督长老教会马偕医疗财团法人马偕纪念医院 短合成肽及其治疗和/或预防干眼症的用途
KR101778004B1 (ko) * 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
CN107969126A (zh) * 2015-06-26 2018-04-27 埃克西金炎症有限公司 Jnk信号转导通路的细胞穿透肽抑制剂用于治疗轻度认知损害的新用途
KR101690539B1 (ko) 2015-07-30 2016-12-29 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
MX2019013799A (es) 2017-05-17 2020-08-13 Yuyu Pharma Inc Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
PT3720428T (pt) * 2017-12-04 2023-04-03 Salvat Lab Sa Composição tópica oftálmica compreendendo ácido dobesílico para tratamento de doenças do segmento posterior do olho
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
KR102429281B1 (ko) 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
DK0671923T3 (da) 1992-10-09 2001-08-13 Advanced Tissue Sciences Inc Leverreserveceller
JPH11510386A (ja) 1995-07-28 1999-09-14 マリー キュリー キャンサー ケア 輸送蛋白質およびそれらの使用
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU2003278727A1 (en) * 2002-09-20 2004-04-08 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
JP5508398B2 (ja) * 2008-05-07 2014-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼の表面潤滑の治療的補充及び強化

Also Published As

Publication number Publication date
JP2015500213A (ja) 2015-01-05
KR20140099526A (ko) 2014-08-12
CN104023736A (zh) 2014-09-03
WO2013079213A1 (en) 2013-06-06
MX2014006399A (es) 2015-04-10
EA201491062A1 (ru) 2014-10-30
IL232699A0 (en) 2014-07-31
SG11201402347YA (en) 2014-06-27
AU2012344299A1 (en) 2014-05-29
CA2855223A1 (en) 2013-06-06
US20140309400A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
BR112014013041A2 (pt) uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco
BR112016029413A2 (pt) utilização de inibidores peptídicos permeáveis às células da via de transdução do sinal da jnk para o tratamento de várias doenças
EA201590518A1 (ru) Стабильные водные составы адалимумаба
EA201300987A1 (ru) Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
EA201491644A1 (ru) Фармацевтические композиции
DOP2011000274A (es) Proteinas de union a il-17
EA201171494A1 (ru) Миметики белка smac
CO6551686A2 (es) Inmunoglobinas con dominio variable dual y usos de las mismas
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CL2008000592A1 (es) Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
WO2014016848A3 (en) Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
CL2014002386A1 (es) Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
TR201905101T4 (tr) Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar.
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
EA201590162A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.